New drug cocktail targets Hard-to-Treat cancers with genetic flaw
NCT ID NCT07532902
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to find a safe dose and see if the combination shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BMS-986504 (an experimental drug taken by mouth) combined with standard chemotherapy and immunotherapy drugs
- What this could lead to
- If it works, this could lead to a new treatment option for people with certain hard-to-treat cancers that have a specific genetic change (MTAP deletion).
- What could go wrong
- This is an early (Phase 1) trial with only 60 participants, so the main goal is safety, not effectiveness. The drug may not work or could have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
RECRUITINGBasking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (All Protocol Activities)
RECRUITINGMontvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
RECRUITINGMiddletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
RECRUITINGUniondale, New York, 11553, United States
-
Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)
RECRUITINGCommack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
RECRUITINGHarrison, New York, 10604, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Can a Two-Drug attack shrink Hard-to-Treat bladder tumors?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
- New antibody aims to unlock immune attack on Hard-to-Treat cancers